Skip to content

Calculus invests in employee engagement platform ‘Mo’

Mo enables individuals, teams and organisations to capture, celebrate and elevate moments at work by becoming the destination for people to share and engage in what is meaningful to them at work. Mo believes meaningful moments have the power to connect people, improve employee engagement and create a culture that improves business performance. Calculus Capital … Continued

Calculus Portfolio Companies and COVID-19 work – an update

Calculus has long been a supporter of the life sciences sector. In April we wrote about how many of our healthcare companies had quickly pivoted their resources to help play their part in the fight against COVID-19. Over the past few months they have been making important contributions which we would like to highlight below. … Continued

Open Orphan signs contract with UK government

Open Orphan/hVIVO Signs Contract with UK Government for the Development of a COVID-19 Human Challenge Study Model COVID-19 human challenge study model to safely speed up development of an efficacious vaccine. hVIVO has the world’s leading portfolio of 8 human challenge study models developed to date and has safely run more human challenge studies than any other company globally … Continued

Hikma and Arecor expand collaboration

New agreement to develop and commercialise ready-to-administer medicine The agreement builds on Hikma and Arecor’s first product co-development agreement, which was announced on 9 January 2020 London and Cambridge, October 20, 2020 Hikma Pharmaceuticals PLC (Hikma or the Group), the multinational pharmaceutical company, and Arecor Limited, the biopharmaceutical company advancing today’s therapies to enable healthier … Continued

Oxford BioTherapeutics and Boehringer Ingelheim build on their successful partnership

In October, Oxford BioTherapeutics (OBT) received a milestone payment from Boehringer Ingelheim (BI) for the progression of the first bispecific oncology drug candidate, developed under their collaboration, into Phase I clinical trials. In addition, OBT established a new, expanded collaboration with BI, whereby OBT will validate certain novel oncology drug targets that are compatible for … Continued